The role of interleukin-17A and interleukin-17E in multiple myeloma patients

Medical Science Monitor

Volumn 18, Issue 1, 2012, Pages

  Lemancewicz, Dorota ^a   Bolkun, Lukasz ^a   Jablonska, Ewa ^a   Czeczuga Semeniuk, Ewa ^a   Kostur, Agnieszka ^a   Kloczko, Janusz ^a   Dzieciol, Janusz ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Interleukin 17A; Interleukin 17E; Multiple myeloma

Indexed keywords

BETA 2 MICROGLOBULIN; INTERLEUKIN 17; INTERLEUKIN 25;

AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MULTIPLE MYELOMA; PLASMA CELL; PROTEIN BLOOD LEVEL; TUMOR GROWTH;

EID: 84855282454     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882204     Document Type: Article

References (18)

1. Pappu BP, Angkasekwinai P, Dong C. Regulatory mechanisms of helper T cell differentiation: New lessons learned from interleukin 17 family cytokines. Pharm Ther, 2008; 117: 374-83
2. Kawaguchi M, Adachi M, Oda N et al: IL-17 cytokine family. J Allergy Clin Immunol, 2004; 114(6): 1265-73
3. Moseley TA, Haudenschild DR, Rose L, Reddi AH: Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev, 2003; 14: 155-74
4. Harrington LE, Hatton RD, Mangan PR et al: Interleukin 17producing CD4+ effector T cells develop via lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 2005; 6(11): 1123-32
5. Hamzaoui K, Bouali E, Ghorbel I et al: Expression of Th-17 and RORgt mRNA in Behçet's Disease. Med Sci Monit, 2012: 18(1): CR227-34
6. Yao Z, Fanslow WC, Seldin MF et al: Herpesvirus samiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity, 1995; 3: 811-21
7. Fort MM, Cheng J, Yen D et al: IL-25 induces IL-4, IL-5, and IL-13 and Th2associated pathologies in vivo. Immunity, 2001; 15: 985-95
8. Prabhala RH, Pelluru D, Fulciniti M et al: Elevated IL-17 produced by TH17 cells promotes myeloma growth and inhibits immune function in multiple myeloma. Blood, 2010; 115(26): 5385-92
9. Garley M, Jablonska E, Grabowska SZ, Piotrowski L: IL-17 family cytokines in neutrophils of patients with oral epithelial squamous cell carcinoma. Neoplasma, 2009; 56(2): 96-100
10. Alexandrakis MG, Pappa CA, Miyakis S et al: Serum interleukin 17 and its relationship to angiogenic factors in multiple myeloma. Eur J Intern Med, 2006; 17(6): 412-16
11. Dhodapkar KM, Barbuto S, Matthews P et al: Dendritic cells mediate the induction of polyfunctional human IL-17 producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood, 2008; 112(7): 2878-85
12. Broxmeyer HE, Starnes T, Ramsey H et al: The IL-17 cytokine family members are inhibitors of human hematopoietic progenitor proliferation. Blood, 2006; 108(2): 770
13. Kim MR, Manoukian R, Yeh R et al: Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production. Blood, 2002; 100(7): 2330-40
14. Takahashi H, Numasaki M, Lotze MT, Sasaki H: Interleukin-17 enhances bFGF, HGF and VEGF induced growth of vascular endothelial cells. Immunol Lett, 2005; 98: 189-93
15. Noonan K, Marchionni L, Anderson J et al: A novel role of IL-17 producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood, 2010; 116(18): 3554-63
16. Dimopoulos MA, Barlogie B, Smith TL, Alexanian R: High serum lactate dehydrogenase level as a marker for drug resistance and short survival in mulitiple myeloma. Ann Intern Med, 1991; 115: 931-35
17. Sirohi B, Powles R, Kulkarni S et al: Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant, 2001; 28: 29-37
18. Durie BG, Stock-Novack D, Salmon SE et al: Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study. Blood, 1990; 75: 823-30